Mesothelioma Immunotherapy

Penn Abramson huCART-meso Phase 1 (NCT03054298; PMID 41566776) — fully human mesothelin CAR-T; 35% CRS, 60% stable disease, 2+ year T-cell persistence.

Your ECOG performance status score is the single strongest predictor of mesothelioma survival. Learn how ECOG 0-4 scores determine treatment eligibility, including surgery, immunotherapy, and clinical trials.

Compare 8 mesothelioma clinical trials in 2026 including CheckMate 743 5-year data showing 14% long-term survival. Side-by-side results, eligibility, and enrollment.

The FDA approved a subcutaneous Opdivo formulation that takes 5 minutes instead of 60. Learn how this new nivolumab injection changes treatment for mesothelioma patients.

UV1 telomerase vaccine earned FDA Fast Track designation for mesothelioma. Learn about the NIPU trial's 23-month survival data and what it means for patients.